Emergent BioSolutions (EBS) EBIAT (2016 - 2025)
Historic EBIAT for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $51.2 million.
- Emergent BioSolutions' EBIAT fell 5540.07% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 13635.06%. This contributed to the annual value of -$190.6 million for FY2024, which is 7493.75% up from last year.
- As of Q3 2025, Emergent BioSolutions' EBIAT stood at $51.2 million, which was down 5540.07% from -$12.0 million recorded in Q2 2025.
- Emergent BioSolutions' 5-year EBIAT high stood at $193.1 million for Q4 2021, and its period low was -$283.1 million during Q2 2024.
- Its 5-year average for EBIAT is -$44.0 million, with a median of -$31.3 million in 2024.
- Per our database at Business Quant, Emergent BioSolutions' EBIAT crashed by 1048000.0% in 2022 and then skyrocketed by 65555.56% in 2025.
- Quarter analysis of 5 years shows Emergent BioSolutions' EBIAT stood at $193.1 million in 2021, then plummeted by 134.7% to -$67.0 million in 2022, then increased by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then soared by 263.58% to $51.2 million in 2025.
- Its EBIAT stands at $51.2 million for Q3 2025, versus -$12.0 million for Q2 2025 and $68.0 million for Q1 2025.